<DOC>
	<DOCNO>NCT00697658</DOCNO>
	<brief_summary>The purpose study explore efficacy , tolerability safety paliperidone Extended Release ( ER ) 250 schizophrenia patient start treatment paliperidone ER naturalistic setting .</brief_summary>
	<brief_title>INVISION - An Observational Study Explore Effectiveness , Tolerability Safety Paliperidone ER Patients With Schizophrenia</brief_title>
	<detailed_description>This observational , prospective , multicenter 6-month study explore efficacy , tolerability safety paliperidone Extended Release ( ER ) 250 schizophrenia patient start treatment paliperidone ER naturalistic setting . The primary objective explore change Clinical Global Impression Severity ( CGI-S ) score baseline 26 week , subgroup schizophrenia patient start treatment paliperidone ER . Secondary objective : 1 ) To explore change mental health social functioning base routine outcome assessment Netherlands , Health Nation Outcome Scales ( HoNOS ) Global Assessment Functioning ( GAF ) , schizophrenia patient start treatment paliperidone ER ; 2 ) To explore change patient 's satisfaction treatment , change number ambulant contact , change body weight , change concomitant therapy explore adverse event schizophrenia patient start treatment paliperidone ER ; explore possible association CGI-S , GAF HoNOS . The patient receive paliperidone ER ( 6 mg , 9 mg dosage direct label ) daily period 6 month . Which dosage paliperidone ER patient receive discretion investigator accord Summary Product Characteristics ( SmPC ) . Because study observational , dosage , administration duration treatment discretion treat physician .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<criteria>Patient meet DSMIV criterion schizophrenia Switched start paliperidone ER , longer two week ago In 24 hour initiation paliperidone ER treatment , CGIS , patient satisfaction treatment , concomitant therapy , body weight , GAF HoNOS data available Patient legal representative sign informed consent form within two week start treatment paliperidone ER No use paliperidone ER , clozapine , conventional depot neuroleptic long act atypical antipsychotic drug 3 month start paliperidone ER No participation investigational drug trial 30 day prior start paliperidone ER No history neuroleptic malignant syndrome No known hypersensitivity paliperidone ER risperidone No patient hospitalize period longer 12 week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Paliperidone ER</keyword>
	<keyword>Schizophrenia</keyword>
</DOC>